<?xml version='1.0' encoding='utf-8'?>
<document id="21905789"><sentence text="Micafungin use in children." /><sentence text="Invasive fungal infections (IFIs) are one of the major reasons for morbidity and mortality in immunocompromised children" /><sentence text=" The majority of IFIs are caused by Candida and Aspergillus species" /><sentence text=" Early diagnosis and prompt initiation of appropriate antifungal therapy is essential for favorable outcome" /><sentence text=" Micafungin is a member of the echinocandins, a novel class of antifungal agents that target the biosynthesis of Î²-1,3-D-glucan, a key fungal cell wall component"><entity charOffset="1-11" id="DDI-PubMed.21905789.s5.e0" text="Micafungin" /><entity charOffset="31-44" id="DDI-PubMed.21905789.s5.e1" text="echinocandins" /><pair ddi="false" e1="DDI-PubMed.21905789.s5.e0" e2="DDI-PubMed.21905789.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21905789.s5.e0" e2="DDI-PubMed.21905789.s5.e1" /></sentence><sentence text=" It has concentration-dependent fungicidal activity against Candida species and fungistatic activity against Aspergillus species" /><sentence text=" Although optimal dosing of micafungin in children has not been established, the recommended dosage in children is 2 mg/kg/day (100 mg/day if &gt;40 kg bodyweight) for invasive candidiasis, 1 mg/kg/day (50 mg/day if &gt;40 kg bodyweight) for the prophylaxis of Candida infections in patients with anticipated prolonged and severe neutropenia or in allogeneic hematopoietic stem cell transplantation recipients"><entity charOffset="28-38" id="DDI-PubMed.21905789.s7.e0" text="micafungin" /></sentence><sentence text=" Micafungin has a favorable safety and drug-drug interaction profile"><entity charOffset="1-11" id="DDI-PubMed.21905789.s8.e0" text="Micafungin" /></sentence><sentence text=" The most common adverse effects in children are diarrhea, epistaxis, abdominal pain, headache, nausea, vomiting, fever, chills, elevation of alanine aminotransferase/aspartate aminotransferase values, hypokalemia, thrombocytopenia, mucositis, and rash"><entity charOffset="142-149" id="DDI-PubMed.21905789.s9.e0" text="alanine" /><entity charOffset="167-176" id="DDI-PubMed.21905789.s9.e1" text="aspartate" /><pair ddi="false" e1="DDI-PubMed.21905789.s9.e0" e2="DDI-PubMed.21905789.s9.e0" /><pair ddi="false" e1="DDI-PubMed.21905789.s9.e0" e2="DDI-PubMed.21905789.s9.e1" /></sentence><sentence text=" Because of its different mechanisms of action, micafungin shows promise as part of the prophylactic and therapeutic management of IFIs, but larger prospective and comparative trials are needed for widespread use in children" /><sentence text="" /></document>